FITC Anti-EpCAM antibody [B29.1 (VU-1D9)] (ab8666)
![Immunocytochemistry/ Immunofluorescence - FITC Anti-EpCAM antibody [B29.1 (VU-1D9)] (ab8666)](https://www.abcam.com/ps/products/8/ab8666/Images/ab8666-15080-anti-epcam-antibody-b291-vu-1d9-fitc-immunofluorescence.jpg "Immunocytochemistry/ Immunofluorescence - FITC Anti-EpCAM antibody [B29.1 (VU-1D9)] (ab8666)")
Key features and details
- FITC Mouse monoclonal [B29.1 (VU-1D9)] to EpCAM
- Suitable for: ICC/IF
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG1
Overview
-
Product name
FITC Anti-EpCAM antibody [B29.1 (VU-1D9)]
See all EpCAM primary antibodies -
Description
FITC Mouse monoclonal [B29.1 (VU-1D9)] to EpCAM -
Host species
Mouse -
Conjugation
FITC. Ex: 493nm, Em: 528nm -
Specificity
This antibody reacts with a 40 kD cell surface glycoprotein called ESA. -
Tested applications
Suitable for: ICC/IFmore details -
Species reactivity
Reacts with: Human -
Immunogen
Tissue, cells or virus corresponding to Human EpCAM. Raised against carcinoma cell line of human origin.
Database link: P16422 -
Positive control
- Breast, colon carcinoma and tonsil
-
General notes
Dilute according to the particular application being used. In general, 0.05M borate pH 8.0 containing 0.15M sodium chloride, 0.02% sodium azide, is a good dilutent to use with most antibodies. Avoid diluting the entire contents of the vial at once since the diluted solution may have reduced stability.
Fluorescein (FITC) conjugated at a ratio of 6 moles of Fluorescein to 1 mole of antibody. Maximum excitation of FITC occurs at wavelength 492 nm and maximum emission occurs at wavelength 520 nm.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Please see notes section. -
Storage buffer
pH: 7.40
Preservative: 0.1% Sodium azide
Constituent: 0.01% PBS -
Concentration information loading... -
Purity
Protein G purified -
Clonality
Monoclonal -
Clone number
B29.1 (VU-1D9) -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab8666 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ICC/IF | Use a concentration of 5 - 10 µg/ml. See Abreview. |
Target
-
Function
May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E. -
Tissue specificity
Highly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma. -
Involvement in disease
Defects in EPCAM are the cause of diarrhea type 5 (DIAR5) [MIM:613217]. It is an intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.
Defects in EPCAM are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM. -
Sequence similarities
Belongs to the EPCAM family.
Contains 1 thyroglobulin type-1 domain. -
Post-translational
modificationsHyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability. -
Cellular localization
Lateral cell membrane. Cell junction > tight junction. Co-localizes with CLDN7 at the lateral cell membrane and tight junction. - Information by UniProt
-
Database links
- Entrez Gene: 4072 Human
- Omim: 185535 Human
- SwissProt: P16422 Human
- Unigene: 542050 Human
-
Alternative names
- 17 1A antibody
- 323/A3 antibody
- Adenocarcinoma associated antigen antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence - FITC Anti-EpCAM antibody [B29.1 (VU-1D9)] (ab8666)ICC/IF image of ab8666 stained HepG2 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab8666, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Protocols
References (15)
ab8666 has been referenced in 15 publications.
- Han T et al. miR-552 Regulates Liver Tumor-Initiating Cell Expansion and Sorafenib Resistance. Mol Ther Nucleic Acids 19:1073-1085 (2020). PubMed: 32044726
- Cheng Z et al. Long non-coding RNA THOR promotes liver cancer stem cells expansion via ß-catenin pathway. Gene 684:95-103 (2019). PubMed: 30359743
- Ran RZ et al. miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway. Exp Cell Res 378:66-75 (2019). PubMed: 30844391
- Jiang ZB et al. miR-365 regulates liver cancer stem cells via RAC1 pathway. Mol Carcinog 58:55-65 (2019). PubMed: 30182377
- Zhang P et al. Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric Cancer. Cell Rep 27:1934-1947.e5 (2019). PubMed: 31067475
